Skip to main content
Erschienen in: Diabetology International 4/2017

24.04.2017 | Short Communication

Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus

verfasst von: Masayuki Tojikubo, Yuji Tajiri

Erschienen in: Diabetology International | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Aims

To compare and evaluate effects of two DPP-4 inhibitors with different excretion routes on systemic and renal hemodynamics in Japanese patients with type 2 diabetes mellitus.

Methods

Seventy-three outpatients with type 2 diabetes who had been treated by 50 mg/day of sitagliptin (S) for at least 1 year were enrolled and prescribed 5 mg/day of linagliptin (L) instead of S for the next 1 year.

Results

After the initiation of S, the systolic and diastolic blood pressure decreased significantly. However, after switching to L for 1 year they increased significantly and returned to a comparable level as those before S treatment. The increase in serum creatinine or uric acid levels and the decrease in eGFR after S initiation were completely stopped or reversed after switching to L. The change in eGFR after the initiation of S was negatively correlated with the eGFR value at 1 year before switching.

Conclusions

The administration of S had an obvious effect on the systemic or renal hemodynamics in contrast to the fact that the administration of L had no effect on these parameters. It is thus important to use these agents with different excretion routes, properly taking the patients' renal function into account.
Literatur
1.
Zurück zum Zitat Kirino Y, Sato Y, Kamimoto T, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2009;200:53–61.CrossRefPubMed Kirino Y, Sato Y, Kamimoto T, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2009;200:53–61.CrossRefPubMed
2.
Zurück zum Zitat Kubota A, Maeda H, Kanamori A, et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012;4:309–13.PubMedPubMedCentral Kubota A, Maeda H, Kanamori A, et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012;4:309–13.PubMedPubMedCentral
3.
Zurück zum Zitat Takihata M, Nakamura A, Tajima K, et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013;15:455–62.CrossRefPubMed Takihata M, Nakamura A, Tajima K, et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013;15:455–62.CrossRefPubMed
4.
Zurück zum Zitat Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e20–2.CrossRefPubMed Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e20–2.CrossRefPubMed
5.
Zurück zum Zitat Girardi AC, Fukuda LE, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol. 2008;294:F414–22.CrossRefPubMed Girardi AC, Fukuda LE, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol. 2008;294:F414–22.CrossRefPubMed
6.
Zurück zum Zitat Girardi AC, Degray BC, Nagy T, et al. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem. 2001;276:46671–7.CrossRefPubMed Girardi AC, Degray BC, Nagy T, et al. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem. 2001;276:46671–7.CrossRefPubMed
7.
Zurück zum Zitat Scott D. Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment. Diabetes Metab Syndr Obes. 2013;6:359–63.CrossRefPubMedPubMedCentral Scott D. Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment. Diabetes Metab Syndr Obes. 2013;6:359–63.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci. 2003;18:169–74.PubMed Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci. 2003;18:169–74.PubMed
9.
Zurück zum Zitat Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int. 1992;41:829–35.CrossRefPubMed Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int. 1992;41:829–35.CrossRefPubMed
11.
Zurück zum Zitat Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.CrossRefPubMed Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.CrossRefPubMed
12.
Zurück zum Zitat Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1413–23.CrossRefPubMed Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1413–23.CrossRefPubMed
Metadaten
Titel
Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus
verfasst von
Masayuki Tojikubo
Yuji Tajiri
Publikationsdatum
24.04.2017
Verlag
Springer Japan
Erschienen in
Diabetology International / Ausgabe 4/2017
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-017-0320-4

Weitere Artikel der Ausgabe 4/2017

Diabetology International 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.